These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 28735071)

  • 1. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
    Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.
    Gupta A; Shah U; Khine H; Vandergriff T; Froehlich T
    Melanoma Res; 2017 Apr; 27(2):171-173. PubMed ID: 28099367
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins.
    Spänkuch I; Gassenmaier M; Tampouri I; Noor S; Forschner A; Garbe C; Amaral T
    Eur J Cancer; 2017 Aug; 81():203-205. PubMed ID: 28641200
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
    Sato M; Uhara H; Koga H; Okuyama R
    J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
    Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
    Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent toxicity of ipilimumab in metastatic melanoma.
    Olischewsky A; De Schrijver S; Bankfalvi A; Wetter A; Zimmer L; Livingstone E; Schadendorf D; Ugurel S
    Eur J Cancer; 2018 May; 95():104-108. PubMed ID: 29477367
    [No Abstract]   [Full Text] [Related]  

  • 7. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
    Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A
    J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534
    [No Abstract]   [Full Text] [Related]  

  • 8. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
    Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
    J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
    Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
    J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    Afzal MZ; Shirai K
    J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors-related orchitis.
    Brunet-Possenti F; Opsomer MA; Gomez L; Ouzaid I; Descamps V
    Ann Oncol; 2017 Apr; 28(4):906-907. PubMed ID: 28039179
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy.
    Danielli R; Cisternino F; Giannarelli D; Calabrò L; Camerini R; Savelli V; Bova G; Dragonetti R; Di Giacomo AM; Altomonte M; Maio M
    Expert Opin Biol Ther; 2018 Jul; 18(sup1):77-83. PubMed ID: 30063847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
    Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
    Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
    Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
    J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
    Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.
    Maeda T; Hiura A; Uehara J; Toyoshima R; Nakagawa T; Yoshino K
    Eur J Dermatol; 2021 Oct; 31(5):662-664. PubMed ID: 34642136
    [No Abstract]   [Full Text] [Related]  

  • 18. Nivolumab: A Review in Advanced Melanoma.
    Scott LJ
    Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis.
    Yang Y; Pei J; Gao G; Yang Z; Guo S; Yue B; Qiu J
    Oncotarget; 2016 Dec; 7(49):80855-80871. PubMed ID: 27764796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients.
    Heppt MV; Schlaak M; Eigentler TK; Kähler KC; Kiecker F; Loquai C; Meier F; Tomsitz D; Brenner N; Niesert AC; Thonke R; Hauschild A; Berking C
    Ann Oncol; 2017 Dec; 28(12):3104-3106. PubMed ID: 28950303
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 34.